Holen Sie sich die Stockscreener-App
136.01
0.47%
-0.64
Schlusskurs vom Vortag:
$136.65
Offen:
$137.37
24-Stunden-Volumen:
542.46K
Relative Volume:
0.92
Marktkapitalisierung:
$8.22B
Einnahmen:
$3.99B
Nettoeinkommen (Verlust:
$463.16M
KGV:
19.16
EPS:
7.1
Netto-Cashflow:
$1.10B
1W Leistung:
+1.53%
1M Leistung:
+12.01%
6M Leistung:
+18.93%
1J Leistung:
+5.91%
1-Tages-Spanne:
$134.58
$137.60
1-Wochen-Bereich:
$132.58
$137.60
52-Wochen-Spanne:
$99.06
$138.27
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Firmenname
Jazz Pharmaceuticals Plc
Sektor
Branche
Telefon
353-1-634-7800
Adresse
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Vergleichen Sie JAZZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
136.01 | 8.22B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Eingeleitet | Goldman | Buy |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-06-12 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-12-09 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Buy |
| 2022-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-11-19 | Fortgesetzt | Goldman | Buy |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-10-05 | Eingeleitet | Citigroup | Buy |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-05-19 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-14 | Herabstufung | Goldman | Neutral → Sell |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Eingeleitet | Jefferies | Buy |
| 2020-03-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Neutral |
| 2019-08-21 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2018-11-08 | Bestätigt | B. Riley FBR | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Bestätigt | H.C. Wainwright | Neutral |
| 2018-03-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
First Week of April 17th Options Trading For Jazz Pharmaceuticals - Nasdaq
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Venturi Wealth Management LLC - MarketBeat
Van ECK Associates Corp Reduces Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Can Jazz Pharmaceuticals' Next Strategic Move Transform Its $2B Portfolio? Key Insights Coming - StockTitan
Jazz (JAZZ) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures - Yahoo Finance
Autism Spectrum Disorder Treatment Market Size is expected - openPR
Convergence Investment Partners LLC Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Philip James Wealth Mangement LLC Has $1.31 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals (JAZZ) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) Hits New 1-Year HighStill a Buy? - MarketBeat
JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline - MSN
Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded at Wells Fargo & Company - MarketBeat
Summit Trail Advisors LLC Takes $539,000 Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Warther Private Wealth LLC Sells 31,065 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) Shares Up 6.2%What's Next? - MarketBeat
Harvey Capital Management Inc. Purchases Shares of 25,450 Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Moloney Securities Asset Management LLC Takes $464,000 Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Polaris Capital Management LLC Reduces Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals stock hits 52-week high of $134.24 By Investing.com - Investing.com Australia
Lewy Body Dementia Pipeline 2025: FDA Approvals and Clinical - openPR
Wells Fargo Upgrades Jazz Pharmaceuticals to Overweight From Equalweight, Adjusts Price Target to $170 From $130 - Marketscreener.com
Wells Fargo Upgrades Jazz Pharmaceuticals (BRSE:J7Z) - Nasdaq
This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Wells Fargo Upgrades Jazz Pharmaceuticals (JAZZ) - Nasdaq
Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings) - Benzinga
Jazz Pharmaceuticals stock hits 52-week high of $134.24 - MSN
Jazz (JAZZ) Surges 5.2%: Is This an Indication of Further Gains? - Nasdaq
Graphene Investments SAS Cuts Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025 - ShareCast
Jazz Pharmaceutical wraps up Epidiolex patent claims - Green Market Report
Jazz Pharma Drops Last Defendant From Epidiolex Patent Suit - Law360
Avadel Pharmaceuticals gains as holder pushes for sale process (AVDL:NASDAQ) - Seeking Alpha
ASL Strategic Value Fund Letter to Avadel Pharmaceuticals (AVDL: NASDAQ) Board of Directors - Yahoo Finance
Meritage Portfolio Management Has $8.16 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd Sells 1,500 Shares of Stock - MarketBeat
Fed Circ. Considers Some Testing For Avadel Sleep Drug - Law360
Jazz Pharmaceuticals: Turning the Tables on Cancer with The - CSRwire.com
Jazz Pharmaceuticals Joins the Movement for Awareness and Suppor - GuruFocus.com
Jazz Pharmaceuticals Joins the Movement for Awareness and Support on World Cancer Day with The Upside Down Challenge - StreetInsider.com
Jazz Pharmaceuticals CEO Bruce Cozadd sells shares worth $183,465 - MSN
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Sees Large Decrease in Short Interest - MarketBeat
Institute for Wealth Management LLC. Makes New $260,000 Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Finanzdaten der Jazz Pharmaceuticals Plc-Aktie (JAZZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):